- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02970630
Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study
Envarsus® Tablets Administered Once Daily in Combination With Everolimus in Elderly De-novo Kidney Transplant Recipients: Open-label, Multicentre, Single-arm, Pharmacokinetic and Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Milano, Italy
- Ospedale Maggiore Policlinico
-
Milano, Italy
- Ospedale Ca' Granda - Niguarda
-
Padova, Italy
- Azienda Ospedaliera di Padova
-
Rome, Italy
- Policlinico "A. Gemelli"
-
Siena, Italy
- Policlinico "Le Scotte"
-
Torino, Italy
- Azienda Ospedaliera S. Giovanni Battista
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject's written informed consent obtained prior to transplant intervention and prior to any study-related procedures;
- Caucasian male or female subjects aged 60 or older who are receiving a primary or secondary single or dual renal transplant from a blood group compatible deceased donor;
- Patients who are planned to receive a renal allograft by Extended Criteria Donor (ECD);
- Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study;
- Patients with low to standard immunological risk, who had a PRA (Panel Reactive Antibody) ≤ 20% (PRA testing according to centre's practice);
- Body Mass Index (BMI) between 15 and 35 kg/m2 extremes inclusive;
- Women must be postmenopausal (physiologic menopause defined as "12 consecutive months of amenorrhea") or permanently sterilized (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) to be enrolled in the study.
Exclusion Criteria:
- Recipients of any transplanted organ other than a single or dual kidney;
- Patients unable or unwilling to provide informed consent;
Male subjects with females partner of childbearing potential UNLESS they or their partner are willing to use a reliable method of contraception (see below for details) from the time of first dose administration and until 8 weeks after the last dose of study drugs. Male subjects with partners of non-childbearing potential are not required to use contraception.
Reliable methods of contraception for male subjects and their partner of childbearing potential must be one of the following:
- Placement of an intrauterine device or intrauterine system
- Hormonal contraception (implantable, patch, oral)
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical vaults/caps) with spermicidal foam/gel/film/cream/suppository.
- Male sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate "True abstinence" is acceptable only if it is in line with the preferred and usual lifestyle of the subject.
- Recipients of a bone marrow or stem cell transplant;
- Recipients of a kidney from a cardiac death donor;
- Recipients of a kidney from an ABO (0, A and blood cell types) incompatible donor;
- Recipients having pre-transplant donor specific anti-HLA (Human leukocyte antigen antibodies) (DSA) or who lost the first kidney transplant because of acute rejection;
- Recipients of a kidney with an anticipated cold ischemia time ≥ 24 hours;
- Recipients positive for Hepatitis C virus (HCV-RNA positive) and/or Hepatitis B Virus (HBV-DNA or HBsAg positive);
- Recipients positive for Human Immunodeficiency Virus (HIV-Ab positive);
- Patients with a current malignancy or a history of malignancy (within the past 5 years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully;
- Patients with uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives;
- Patients with severe diarrhoea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of study drugs;
- Patients with a white blood cell count ≤ 2.8x109/L unless the absolute neutrophil count (ANC) is ≥ 1.0x109/L;
- Patients with a platelet count ≤ 50.0x109/L;
- Patients with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) enzyme levels > 3 times the upper limit of normal during the 30 days prior to the transplant procedure;
- Patients who were treated with any other investigational agent in the three months prior to enrolment;
- Patients who received any investigational new drug, or participated in clinical study within the last 8 weeks;
- Patient planned to receive an induction therapy different from rabbit ATG (Anti-thymocyte globulin) alone or patients who did not start rabbit ATG induction therapy after transplant;
- Patients who are already on immunosuppressive drugs the day before transplantation, except ATG as per protocol;
- Patients who are planned to receive therapy with any immunosuppressive agent other than those prescribed in the study;
- Patients with a known hypersensitivity to corticosteroids, tacrolimus or everolimus or sirolimus or any of the excipients present in study drugs formulations;
- Patients with hypersensitivity to macrolides;
- Patients with any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator;
- Subjects unlikely to comply with the study protocol or unable to understand the nature and scope of the study but also the possible benefits or unwanted effects of the study treatments;
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Envarsus once a day, everolimus b.i.d.
Tacrolimus tablets at starting dose of 0.07 mg/kg/day will be administered once daily in the morning. Everolimus tablets at starting dose of 2 mg/day (1 mg b.i.d.) will be administered twice daily, every 12 hours. |
once a day
Other Names:
twice daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tacrolimus Area Under the curve at 24 hours (AUC24)
Time Frame: 10 days
|
10 days
|
Tacrolimus Minimum whole blood concentration (Cmin)
Time Frame: 10 days
|
10 days
|
Tacrolimus Cmin/daily dose
Time Frame: 10 days
|
10 days
|
Tacrolimus AUC24/daily dose
Time Frame: 10 days
|
10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tacrolimus within-patient variability of blood trough level
Time Frame: from day 3 to month 6
|
from day 3 to month 6
|
|
Time to reach therapeutic exposure to tacrolimus
Time Frame: from day 3 to month 6
|
from day 3 to month 6
|
|
Number of dose adjustments
Time Frame: from day 3 to month 6
|
from day 3 to month 6
|
|
Total daily dose
Time Frame: from day 3 to month 6
|
from day 3 to month 6
|
|
Renal function using estimated glomerular filtration rate
Time Frame: from day 1 to month 6
|
from day 1 to month 6
|
|
Treatment failure rate
Time Frame: from day 1 to month 6
|
from day 1 to month 6
|
|
Delayed graft function
Time Frame: from day 1 to month 6
|
Number of days between the first and the last renal replacement session
|
from day 1 to month 6
|
Acute rejection requiring treatment
Time Frame: from day 1 to month 6
|
from day 1 to month 6
|
|
Biopsy proven acute rejections
Time Frame: from day 1 to month 6
|
from day 1 to month 6
|
|
Tacrolimus Maximum whole blood concentration (Cmax)
Time Frame: 10 days
|
10 days
|
|
Tacrolimus Tmax (time that the drug is present at the maximum concentration in serum)
Time Frame: 10 days
|
10 days
|
|
Tacrolimus Average whole blood drug concentration (Cave)
Time Frame: 10 days
|
10 days
|
|
Tacrolimus % fluctuation
Time Frame: 10 days
|
10 days
|
|
Tacrolimus % swing
Time Frame: 10 days
|
10 days
|
|
Tacrolimus linear correlation coefficient between Cmin and AUC24
Time Frame: 10 days
|
10 days
|
|
Adverse Events
Time Frame: from screening to month 6
|
from screening to month 6
|
|
Serious Adverse Events
Time Frame: from screening to month 6
|
from screening to month 6
|
|
Number of opportunistic infections
Time Frame: from screening to month 6
|
Number of opportunistic infections
|
from screening to month 6
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paolo Rigotti, MD, Az Osp Padova, Osp. Civile Padova
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DFIDM-1501
- 2015-005640-34 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on Tacrolimus
-
Novartis PharmaceuticalsCompletedLiver Transplant RecipientBelgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
-
Novartis PharmaceuticalsCompletedLiver TransplantationUnited States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
-
Astellas Pharma IncAstellas Pharma Korea, Inc.CompletedLiver TransplantationKorea, Republic of
-
Heleen GrootjansChiesi Farmaceutici S.p.A.RecruitingLung Transplant; ComplicationsNetherlands
-
The Methodist Hospital Research InstituteVeloxis PharmaceuticalsWithdrawnAcute Rejection of Renal Transplant | Kidney Disease, End-Stage | Donor Specific Antibodies
-
Taro Pharmaceuticals USACompleted
-
Peking Union Medical College HospitalUnknown
-
Technical University of MunichCompleted
-
Limerick BioPharmaCompleted
-
University of British ColumbiaPaladin Labs Inc.RecruitingLiver Transplantation | Neurotoxicity | Tremor | Tacrolimus | ImmunosuppressionCanada